LYRA: Lyra Therapeutics, Inc Company Value to Net Income

Corporate emblem and logo of Lyra Therapeutics Inc. (LYRA)

Lyra Therapeutics, Inc. (LYRA) operations are independent of market cycles, as the demand for ENT pathology therapies remains constant regardless of GDP. The business relies on high margins driven by XTreo, an innovative implant that replaces long-term hormone therapy. The price visualization available on the page with the 0.00 indicator complements data regarding a stable staff of biochemists and the targeted hiring of compliance specialists.

LYRA Lyra Therapeutics Inc: Price to Earnings Ratio in the range 07/04/2022 - 03/21/2026

Comprehensive metric breakdowns and analytics for Lyra Therapeutics Inc. (LYRA)

- price and consensus price forecast:
Comprehensive company analysis:Lyra Therapeutics Inc. - LYRA
Flagship merchandise of Lyra Therapeutics

For Lyra Therapeutics, Inc. (LYRA), which develops biodegradable implants for the therapy of ENT diseases, this ratio reflects the market value of future profits from the commercialization of innovative drug delivery systems. The relationship between the current share price and earnings per share within the company's historical P/E range allows for the determination of whether the asset is overvalued or if the business is undervalued relative to its actual profitability.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E Multiple|Price to Earnings Multiple SXTC (China SXT Pharmaceuticals)|P/E Multiple EPRX|P/E Multiple bioharvest.com (BHST)|Price to Earnings Ratio Invizyne Technologies EXOZ|ORMP: Price to Earnings Multiple|ENTX: Price to Earnings Ratio|HYFT: Price to Earnings Ratio|ABVC BioPharma Inc. (ABVC) - Price to Earnings Ratio|cumberlandpharma.com (CPIX) - P/E Multiple|QNTM (Quantum BioPharma) - P/E Multiple|FGEN: Company Value to Net Income|P/E Multiple TELO|P/E Multiple Rani Therapeutics Holdings (RANI)|P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Market Cap to Earnings|LEXX - Price to Earnings Ratio|PULM (Pulmatrix) - Price to Earnings Multiple|Pheton Holdings Ltd (PTHL) - Price to Earnings Ratio|Aptorum - Company Value to Net Income|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)